FRX.TO
Price:
$11.92
Market Cap:
$242.77M
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Industry
Biotechnology
IPO Date
2001-06-12
Stock Exchange
TSX
Ticker
FRX.TO
According to Fennec Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current ROE is 589.85%. This represents a change of 369.24% compared to the average of 125.70% of the last 4 quarters.
The mean historical ROE of Fennec Pharmaceuticals Inc. over the last ten years is 56.45%. The current 589.85% ROE has changed 944.92% with respect to the historical average. Over the past ten years (40 quarters), FRX.TO's ROE was at its highest in in the March 2024 quarter at 426.35%. The ROE was at its lowest in in the September 2022 quarter at -291.22%.
Average
56.45%
Median
-54.02%
Minimum
-120.26%
Maximum
966.87%
Discovering the peaks and valleys of Fennec Pharmaceuticals Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 126.16%
Maximum Annual ROE = 966.87%
Minimum Annual Increase = -973.60%
Minimum Annual ROE = -120.26%
Year | ROE | Change |
---|---|---|
2024 | 7.92% | -94.26% |
2023 | 138.06% | -85.72% |
2022 | 966.87% | -973.60% |
2021 | -110.68% | 79.52% |
2020 | -61.65% | -41.24% |
2019 | -104.93% | 126.16% |
2018 | -46.39% | 76.18% |
2017 | -26.33% | -66.29% |
2016 | -78.12% | -35.04% |
2015 | -120.26% | -66.12% |
The current ROE of Fennec Pharmaceuticals Inc. (FRX.TO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
370.95%
5-year avg
188.10%
10-year avg
56.45%
Fennec Pharmaceuticals Inc.’s ROE is less than Aptose Biosciences Inc. (367.08%), greater than Medicenna Therapeutics Corp. (-59.41%), less than Helix BioPharma Corp. (1.33%),
Company | ROE | Market cap |
---|---|---|
367.08% | $5.72M | |
-59.41% | $57.02M | |
1.33% | $71.93M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Fennec Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Fennec Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Fennec Pharmaceuticals Inc.'s ROE?
How is the ROE calculated for Fennec Pharmaceuticals Inc. (FRX.TO)?
What is the highest ROE for Fennec Pharmaceuticals Inc. (FRX.TO)?
What is the 3-year average ROE for Fennec Pharmaceuticals Inc. (FRX.TO)?
What is the 5-year average ROE for Fennec Pharmaceuticals Inc. (FRX.TO)?
How does the current ROE for Fennec Pharmaceuticals Inc. (FRX.TO) compare to its historical average?